1.Effect and mechanism of atractyloin LPS-induced acute lung injury in mice
Meigui YOU ; Hongmiao WANG ; Yijia TANG ; Caihua WANG ; Yaping XU ; Hongyuan ZHONG
Journal of China Pharmaceutical University 2025;56(6):758-765
This study aimed to investigate the anti-inflammatory and antioxidant effects of atractylon on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. Changes in lung function parameters were measured in mice after intraperitoneal administration of atractylon. Pathological changes in lung tissue were observed by H&E staining, and the degree of pulmonary edema was assessed by the lung wet/dry weight ratio (W/D). Kit assays were used to detect changes in oxidative stress markers in mouse serum and the protein concentration in bronchoalveolar lavage fluid (BALF). ELISA was employed to measure the expression levels of inflammatory cytokines in BALF and serum. Western blot was used to detect the expression levels of proteins related to the cGAS-STING pathway and vascular cell adhesion molecule-1 (VCAM-1) in lung tissue. Results showed that, compared to the ALI model group, mice in the low-dose and high-dose atractylon groups exhibited significant improvement in lung function parameters, alleviated pulmonary edema, and reduced inflammatory cell infiltration in lung tissue. Protein content and inflammatory cytokine levels in serum and BALF were decreased, while serum oxidative stress indicators were improved. Western blot results further indicated that atractylon could regulate the cGAS-STING pathway, blocking the generation of inflammatory signals, and simultaneously inhibit VCAM-1 expression, thereby reducing pulmonary vascular injury. The results suggest that atractylon may alleviate LPS-induced ALI by modulating the cGAS-STING signaling pathway, reducing the expression of pro-inflammatory cytokines and the production of pro-inflammatory mediators, and improving vascular endothelial injury. This study provides a new potential target and theoretical basis for the treatment of ALI, as well as a potential drug candidate for ALI therapy.
2.Study of circTRRAP knockdown in acute myocardial infarction by regulating miR-323-3p/SMAD2 axis
Journal of Chongqing Medical University 2025;50(4):547-556
Objective:To investigate the specific role of circTRRAP in acute myocardial infarction(AMI).Methods:The method of hy-poxia for 24 hours was used to induce the model of myocardial infarction,and the dual-luciferase reporter assay was used to investigate the interaction between circTRRAP,SMAD2,and miR-323-3p.After knockdown and overexpression of miR-323-3p and overexpres-sion of SMAD2 through transfection with si-circTRRAP,the expression levels of proinflammatory cytokines[interkeukin-6(IL-6)and tumor necrosis factor-α(TNF-α)],oxidative stress markers[malondialdehyde(MDA)and superoxide dismutase(SOD)],and apop-totic factors[Bcl-2-associated X protein(Bax),B-cell lymphoma-2(Bcl-2),and cleaved caspase-3]were measured to investigate the role of circTRRAP,SMAD2,and miR-323-3p in myocardial infarction.Results:In the model of myocardial infarction injury,the lev-els of circTRRAP and SMAD2 were significantly increased by more than 50%,whereas there was a significant reduction in the expres-sion of miR-323-3p.The downregulation of circTRRAP led to a reduction in SMAD2 expression by promoting miR-323-3p expres-sion.SMAD2 was negatively correlated with miR-323-3p,but it was positively correlated with the expression of circTRRAP.The down-regulation of circTRRAP or SMAD2 or the upregulation of miR-323-3p could increase cell viability and reduce the apoptosis rate of cardiomyocytes.Conclusion:Downregulation of circTRRAP can inhibit inflammation and alleviate AMI via the miR-323-3p/SMAD2 axis.
3.Continuous low-intensity pulsed ultrasound combined with microbubble cavitation therapy promoting microcirculatory perfusion in ischemic skeletal muscle of mice:a preliminary result
Yijia LIU ; Xiaoyi TANG ; Shangze LI ; Jiaqi ZHAO
Academic Journal of Naval Medical University 2025;46(3):336-343
Objective To evaluate the promoting effect of continuous low-intensity pulsed ultrasound(LIPUS)combined with microbubble(MB)cavitation therapy(hereinafter referred to as ultrasound cavitation therapy)on microcirculatory perfusion in the ischemic hindlimbs of mice,and to explore the non-invasive therapeutic potential of this treatment for limb arterial ischemic injury.Methods A mouse model of left hindlimb ischemia was established,and the mice were randomly assigned to 4 groups(16 mice per group)according to different treatment methods:model group,ultrasound contrast microbubble group(MB group),LIPUS treatment group(LIPUS group),and ultrasound cavitation therapy group(LIPUS+MB group).Mice in the model group were injected with 0.1 mL of normal saline via the tail vein,those in the MB group were injected with 0.1 mL of MB via the tail vein,those in the LIPUS group were treated with LIPUS on the ischemic hindlimb after injection of 0.1 mL of normal saline via the tail vein,and those in the LIPUS+MB group were treated with LIPUS on the ischemic hindlimb after injection of 0.1 mL of MB via the tail vein;each group was injected once a day for a total of 7 d.On the 1st,4th and 7th days after treatment,the microcirculatory perfusion in the ischemic hindlimbs of mice was evaluated using contrast-enhanced ultrasound.The effects of different treatments on promoting microcirculatory perfusion in the ischemic hindlimbs of mice were assessed by combining hematoxylin-eosin(H-E)staining and CD31 immunohistochemical staining of the gastrocnemius muscle tissue in the hindlimbs.Results The left hindlimb ischemia model was successfully constructed,and all model mice showed obvious ischemic microcirculation perfusion disorders with good model stability.After the 7th day of treatment,the LIPUS+MB group showed a increase in microcirculation perfusion in the ischemic hindlimb,with the ratio of microvascular flow on the ischemic to non-ischemic sides higher than that of the LIPUS group([94.33±4.51]%vs[70.33±2.09]%,P<0.05).H-E staining results showed that the LIPUS+MB group had more newly formed capillaries and myofibroblasts in the gastrocnemius muscle,with better muscle structure repair compared to the LIPUS group,while the model group and MB group showed muscle cell necrosis,disorganized arrangement of muscle bundles,and sparse capillaries.CD31 immunohistochemical analysis further confirmed that ultrasonic cavitation therapy significantly outperformed traditional LIPUS treatment in promoting microcirculation perfusion,microvascular neogenesis,and tissue repair in ischemic skeletal muscles(CD31 relative expression level 5.03±0.33 vs 3.57±0.21,P<0.01).Conclusion Compared with single LIPUS treatment,continuous ultrasound cavitation therapy has a more significant effect on promoting microcirculation perfusion in the ischemic hindlimb of mice,which provides a new strategy for microcirculatory perfusion disorders in skeletal muscles of limbs caused by peripheral arterial ischemic diseases.
4.Application and progress of ultrasound-stimulated microbubble cavitation in novel adjuvant therapies
Yijia LIU ; Xiaoyi TANG ; Jiaqi ZHAO
Academic Journal of Naval Medical University 2024;45(11):1419-1424
Ultrasound-stimulated microbubble cavitation(USMC)is a cavitation phenomenon triggered by oscillating microbubbles in ultrasound field,and this effect has led to breakthroughs in improving the permeability of cell membranes,enhancing the sensitivity of tumor cells to chemotherapy or immunotherapy,and increasing the penetration of thrombolytic drugs into blood clots and vascular recanalization.In recent years,the cross-fertilization of ultrasound medicine and materials science have given rise to the study of ultrasound-responsive multifunctional nanobubble to enhance USMC treatment.This article reviews the application and research progress of USMC in improving tissue perfusion in ischemic diseases,tumor chemotherapy and immunotherapy,ultrasonic thrombolysis,and other treatments.
5.An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
Taisheng LI ; Fuping GUO ; Yijia LI ; Chengda ZHANG ; Yang HAN ; Wei LYE ; Yun HE ; Hongzhou LU ; Jing XIE ; Aiqiong HUANG ; Yanling LI ; Xiaoping TANG ; Hui WANG ; Tong ZHANG ; Guiju GAO ; Junkang LEI ; Xiaoying ZHANG ; Xinhua WU ; Yongtao SUN ; Jinsong BAI ; Ling LUO ; Huanling WANG
Chinese Medical Journal 2014;127(1):59-65
BACKGROUNDAn zidovudine (AZT)-substitution regimen containing 24-week stavudine (d4T) followed by long-term AZT for HIV therapy is potential to trade off short-term AZT-related anemia and long-term risks associated with d4T in resource-limited settings. However, evidence is scarce. This study aims to assess the efficacy and safety of AZT-substitution regimen, aiming to find a regimen with better efficacy, less adverse events, and more affordability in resource-limited settings.
METHODSThis prospective, multicenter study enrolled 499 (190 on d4T regimen, 172 on AZT regimen, and 137 on AZT-substitution regimen) HIV-1-infected subjects who initiated combined antiretroviral therapy and attended follow-up visits over 96 weeks from 2009 to 2011. Lamivudine (3TC) and either nevirapine (NVP) or efavirenz (EFV) were the other two drugs in the antiretroviral regimens. Virologic and immunologic responses and adverse events were monitored at baseline and at weeks 4, 12, 24, 36, 48, 60, 72, 84, and 96.
RESULTSIn terms of hematological adverse effects, AZT-substitution group had similar safety profiles to d4T group and was superior to AZT group. In comparison with AZT-substitution group, AZT group was associated with higher risk of developing anemia (adjusted hazard ratio (aHR) for anemia ≥ grade II, 8.44, 95% CI 1.81-39.46) and neutropenia (aHR for neutropenia ≥ grade II, 1.86, 95% CI 1.19-2.93). The prevalence of lipodystrophy in d4T group was 19.5%, while that in AZT-substitution group was zero. As to antiretroviral efficacy, these three groups showed no differences.
CONCLUSIONAZT-substitution regimen provides a relatively safe and effective first-line antiretroviral strategy in resource-limited settings.
Adult ; Anti-HIV Agents ; administration & dosage ; adverse effects ; therapeutic use ; Female ; HIV Infections ; drug therapy ; Humans ; Male ; Middle Aged ; Prospective Studies ; Stavudine ; administration & dosage ; adverse effects ; therapeutic use ; Zidovudine ; administration & dosage ; adverse effects ; therapeutic use

Result Analysis
Print
Save
E-mail